← Back to Screener
Cingulate Inc. Common Stock (CING)
Price$5.26
Favorite Metrics
Price vs S&P 500 (26W)19.53%
Price vs S&P 500 (4W)-41.15%
Market Capitalization$60.47M
All Metrics
Book Value / Share (Quarterly)$0.35
P/TBV (Annual)1.73x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.40
Price vs S&P 500 (YTD)17.17%
EPS (TTM)$-4.42
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-4.42
EPS (Annual)$-4.44
ROI (Annual)-225.48%
Cash / Share (Quarterly)$1.51
ROA (Last FY)-148.94%
EBITD / Share (TTM)$-4.00
ROE (5Y Avg)-445.71%
Cash Flow / Share (Annual)$-2.40
P/B Ratio24.10x
P/B Ratio (Quarterly)11.69x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-12.16x
ROA (TTM)-172.37%
EPS Incl Extra (Annual)$-4.44
Current Ratio (Annual)1.16x
Quick Ratio (Quarterly)1.07x
3-Month Avg Trading Volume0.39M
52-Week Price Return29.35%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.01
52-Week High$11.89
EPS Excl Extra (Annual)$-4.44
CapEx CAGR (5Y)-16.52%
26-Week Price Return23.52%
Quick Ratio (Annual)1.07x
13-Week Price Return6.78%
Total Debt / Equity (Annual)2.97x
Current Ratio (Quarterly)1.16x
Enterprise Value$56.963
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.51
3-Month Return Std Dev120.75%
Net Income / Employee (TTM)$-2
ROE (Last FY)-894.81%
Net Interest Coverage (Annual)-14.20x
EPS Basic Excl Extra (Annual)$-4.44
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)2.97x
EPS Incl Extra (TTM)$-4.42
Receivables Turnover (Annual)0.00x
ROI (TTM)-232.27%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.34
Price vs S&P 500 (52W)-0.48%
Year-to-Date Return19.82%
5-Day Price Return-12.75%
EPS Normalized (Annual)$-4.44
ROA (5Y Avg)-235.97%
Month-to-Date Return-16.26%
Cash Flow / Share (TTM)$-1.52
EBITD / Share (Annual)$-4.00
LT Debt / Equity (Annual)0.46x
ROI (5Y Avg)-194.21%
LT Debt / Equity (Quarterly)0.46x
EPS Basic Excl Extra (TTM)$-4.42
P/B Ratio (Annual)11.69x
Book Value / Share (Annual)$0.35
Price vs S&P 500 (13W)6.09%
Beta-0.81x
Revenue / Share (TTM)$0.00
ROE (TTM)-509.73%
52-Week Low$3.20
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CINGCingulate Inc. Common Stock | — | — | — | — | $5.26 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments using its proprietary precision timed-release drug delivery platform. The company focuses on ADHD and anxiety disorders, where less frequent dosing could improve patient outcomes and medication adherence. Cingulate is also evaluating additional therapeutic applications for its platform technology.